NewsRoom Articles - Page 13 of 44

ThursdayDec 07, 2023 10:30 am

GEMXX Corp. (GEMZ) Releases Positive Q2 2023 Results, Provides 2023 Business and Mining Updates

GEMXX reported significant growth in its Q2 2023 revenue and net income, with the company anticipating additional growth and increased production of its gold assets in 2024 GEMXX, in partnership with Crazy Horse Mining Inc., proved the commercial viability of the Snow Creek gold mine and is looking to similarly prove the viability of the Rosella Creek gold asset in 2024 For the balance of 2023 and into 2024, the company is targeting additional acquisitions, more mine production, and more revenues, and plans to expand gemstone and jewelry production by 300% in 2024 GEMXX (OTC: GEMZ), a company specializing in…

WednesdayDec 06, 2023 11:15 am

Podcast: Jewelry Maker GEMXX Corp. (GEMZ) Enjoys Rapid Growth Thanks to Gold Interest, Focus on Vertical Mine-to-Market Integration

GEMXX Corporation is unique as a jewelry maker with important Canadian mining assets, supporting its mine-to-market operations dealing in gold and the rare Ammolite gemstone Amid recent market fluctuations, gold continues to maintain a strategic profile as an investment safe haven, with consumption continuing at a historic pace GEMXX is riding high on recent “explosive” revenue growth and a no long-term debt position, looking forward to fulfilling select goals to improve its overall production, uplisting to a major exchange and aggressively seeking out strategic acquisitions to add revenue and / or reduce its costs A new NetworkNewsAudio News Podcast and…

TuesdayDec 05, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7%…

MondayDec 04, 2023 10:30 am

Diamond Lake Minerals Inc. (DLMI) Riding Growing Sea Swell Favoring Digital Assets, Security Tokens

Security tokens are becoming increasingly popular as minimized risk entry points for digital infrastructure markets, with smart algorithms beginning to effectively deal with redemption dispute resolution concerns Utah-based Diamond Lake Minerals recently shifted its focus from mining holdings to digital assets and security tokens offerings, and has seen its market interest rise in the process DLMI aims to build an industry-agnostic, vertically integrated holding company that helps its subsidiaries develop self-sufficiency while offering an inroad to experienced investors wary of digital asset involvement — functioning as a “generational wealth” bridge Some market insiders see tokenization as the launch of a…

FridayDec 01, 2023 9:45 am

Vision Marine Technologies Inc. (NASDAQ: VMAR) Is ‘One to Watch’

In November 2023, Vision Marine filed with the SEC to sell 370,000 ordinary shares priced at $4.05 in a private placement The company in November 2023 reported its receipt of a purchase order from boat manufacturer Wired Pontoons for 25 units of its E-Motion 180E powertrain system Vision Marine announced in October 2023 delivery of E-Motion 180E powertrain technology to boat manufacturer Groupe Beneteau, to be integrated on the Four Winns H2e Bowrider model In August 2023, a catamaran powered by a Vision Marine powertrain set an electric boat world speed record of 116 mph at the Lake of the…

FridayDec 01, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”).…

WednesdayNov 22, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was…

MondayNov 20, 2023 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite

Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property…

ThursdayNov 16, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) CEO Underscores Commitment to Continued Growth in Letter to Shareholders

Fr8Tech CEO recently wrote a letter to shareholders summarizing the company’s financial milestones and operational successes CEO Javier Selgas discussed the company’s robust revenue growth in Q2 2023 as well as the 93% year-over-year increase in its gross margins during the first half of the year The company’s commitment to innovation has led to the launch of an LTL offering and the establishment of an AI department Fr8Tech has successfully expanded into new markets, completed a number of strategic integrations with third-party solutions, and grown its customer base Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company whose lead product is…

TuesdayNov 14, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes The move is aimed to help the company partner with the behemoths in an industry projected to bring in between $150 billion and $200 billion a year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000